PBLS
Parabilis Medicines, Inc.
Parabilis Medicines, Inc. (PBLS) has 2 SEC Form 4 filings (12 transaction rows) in the rolling window, disclosed by 1 distinct insider. Most recent filing: Jun 15, 2026.
Insiders have net bought $423.8M over the trailing 6 months. The largest single insider purchase in this window was $423.8M by Director, 10% Owner RA CAPITAL MANAGEMENT, L.P. on Jun 11, 2026.
- Industry:Biotechnology
- CEO:Mathai Mammen
- Employees:145
- HQ:Cambridge, MA, US
- IPO:2026-06-10
Insider Buying
$423.8M
reported purchases (SEC code P)
Insider Selling
$0
reported sales (SEC code S)
Unique Insiders
1
in the rolling window
| Source | ||||||
|---|---|---|---|---|---|---|
| Director, 10% Owner | Purchase | 21,188,750 | $423.8M | Jun 15 | SEC ↗ |
Related companies
Parabilis Medicines, Inc. is in the Healthcare sector.